Last updated: February 21, 2026
What Are the Criteria for Patentability of Biopharmaceuticals in Thailand?
Biopharmaceutical patents in Thailand must meet specific criteria under the Patent Act B.E. 2522 (1979), amended several times, most notably in 2012. These criteria include novelty, inventive step, industrial applicability, and sufficient disclosure.
Novelty
The invention must not be disclosed publicly before filing the patent application. Prior disclosures include publications, existing patents, or public uses in Thailand or abroad. For biopharmaceuticals, disclosures through scientific journals, clinical trial results, or public discussions can jeopardize novelty.
Inventive Step
The invention must involve an inventive step that is not obvious to a person skilled in the field. For biopharmaceuticals, this emphasizes the non-obviousness of processes, molecular structures, or therapeutic uses.
Industrial Applicability
The invention must be capable of industrial application, meaning it can be manufactured or used in industry, including pharmaceuticals.
Sufficient Disclosure
The patent application must disclose the invention clearly and completely enough for a person skilled in the art to reproduce it. For biopharmaceuticals, this involves detailed descriptions of molecular structures, synthesis methods, or formulations, complying with the Thai Patent Act and the Patent Office's examination standards.
What Are the Enforceability Challenges for Biopharmaceutical Patents in Thailand?
Enforceability depends on patent validity and the ability to defend against infringing activities. Challenges include:
Patent Validity
Thai courts scrutinize patents for compliance with statutory requirements. Biopharmaceutical patents often face validity challenges due to the complexity of biological inventions, particularly in demonstrating inventive step and overcoming prior art disclosures.
Data Exclusivity
Thailand does not have data exclusivity rights separate from patent rights. Generic manufacturers can rely on the biologic’s patent status when challenging the patent or applying for generic approvals.
Patent Term and Compulsory Licensing
Patents last 20 years from filing, subject to maintenance fees. The Thai Patent Act allows for compulsory licenses under certain conditions, including public health needs, which can threaten enforceability.
Patent Litigation
Enforcement involves civil infringement actions. The courts require concrete evidence of infringement, often demanding detailed comparison of the patent claims and infringing products. Due to the complexity of biopharmaceuticals, establishing infringement can be technically demanding.
How Broad Are the Claims for Biopharmaceutical Patents in Thailand?
The scope of claims defines the legal boundaries of patent protection. For biopharmaceutical patents, claim breadth depends on invention type:
Composition of Matter Claims
These claims cover the active molecules or biologics themselves. They are typically narrow to withstand prior art challenges but can be broad if sufficiently supported by data.
Process Claims
Processes for manufacturing or preparing biologics can be broader than composition claims, covering various methods, provided they meet the inventive step and disclosure requirements.
Use Claims
Claims directed to specific therapeutic applications are generally narrower, focusing on novelty and inventive step of the use, such as treating a particular disease.
Patent Term Adjustments
Claims on formulations or combination therapies can sometimes extend the scope, but these are subject to novelty and inventive step criteria.
Limitations
Thai patent law emphasizes clarity and support, which may restrict overly broad claims that cannot be substantiated with detailed description, especially regarding molecular structures and biological functions.
Comparison to International Standards
Compared to patentability standards in jurisdictions like the US or EU, Thailand's criteria are similar but with notable differences:
- The Thai patent system emphasizes clear disclosure with less emphasis on patent term adjustments.
- Thai law is more restrictive on claim breadth, requiring precise support.
- Enforceability hinges heavily on validity challenges and technical demonstration, especially for biologics.
Policy Context and Trends
Recent amendments align Thai patent law with international norms, increasing protection scope for biopharmaceuticals but also tightening examination standards. The Thai FDA's consideration process for biologics affects patent enforcement, especially concerning biosimilar approvals.
Key Policy Changes
- 2012 amendments introduced a formality examination system that enhances patent transparency but can delay grant.
- Ongoing discussions about integrating data exclusivity provisions, potentially influencing patent enforcement dynamics.
Key Takeaways
- Patentability hinges on novelty, inventive step, and detailed disclosure, with strict adherence to statutory standards.
- Enforceability challenges involve validity disputes and technical complexities in biological inventions.
- Patent claims must be precisely supported; overly broad claims risk rejection or invalidation.
- Thailand's patent system emphasizes detailed descriptions, with less flexibility for broad claims compared to Western jurisdictions.
- Changes in law and policy aim to balance patent protection with access to medicines, impacting enforcement strategies.
FAQs
1. How does Thailand assess inventive step for biopharmaceutical patents?
They primarily evaluate whether the invention would have been obvious to a skilled person in the biological or pharmaceutical field at the filing date, considering prior art disclosures.
2. Can biopharmaceutical processes be patented in Thailand?
Yes, process patents are granted if they are novel, involve an inventive step, and are sufficiently disclosed.
3. Are secondary or follow-up claims accepted for biopharmaceutical patents?
Secondary claims are allowed but must meet all statutory requirements, particularly support by detailed description and clear boundaries.
4. How does Thailand handle patent enforcement in biopharmaceutical cases?
Enforcement involves civil litigation. Courts review patent validity, infringement, and technical evidence. Patents are enforceable as long as valid.
5. Is there any patent protection for biosimilars in Thailand?
Biosimilars face patent barriers similar to other biologics, and patent challenges can be pursued. The lack of data exclusivity may allow for quicker generic entry once patents expire.
References
- Thai Patent Act B.E. 2522 (1979), Amended in 2012.
- World Intellectual Property Organization. (2021). Thailand Patent Law.
- Pharmaceutical Patent Law – Thailand. (2020). International IP Law Review.
- Thai FDA. (2022). Guidance for Biopharmaceutical Registration.
- WIPO. (2021). Patent Law and Practice in Thailand.
